The objectives of this study were to assess clinica outcomes and prognostic factors in unselected, consecutive patients with poorly differentiated carcinoma (PDC) or poorly differentiated adenocarcinoma (PDA).
The 1,400 patients analyzed were referred to our unknown-primary tumor (UPT) clinic from January 1,1987 through July 31,1994.
Clinical data from these patients were entered into a computerized data base for storage, retrieval, and analysis.
Survival was measured from the time of diagnosis ; survival distribution was estimated using the product-limit method.
Multivariate survival analyses were performed using proportional hazards regression and by recursive partitioning.
Nine hundred seventy-seven patients were diagnosed with unknown-primary carcinoma (UPC) and 337 of these patients had PDC or PDA.
No clinical differences were identified among patients with PDC, PDA, or UPC patients with other carcinoma or adenocarcinoma subtypes.
PDC patients enjoyed better survival than PDA patients.
Poor cellular differentiation was not an important prognostic variable.
Variables predictive of survival included lymph node metastases, sex, number of metastatic sites, histology (PDC v PDA), and age.
Although chemotherapy did not appear to influence survival for the entire group of PDC or PDA patients, a subset of patients with good prognostic features experienced median survival durations of up to 40 months. (...)
Mots-clés Pascal : Carcinome, Adénocarcinome, Origine inconnue, Histopathologie, Différenciation, Cytodifférenciation, Pronostic, Evolution, Survie, Homme, Epidémiologie, Tumeur maligne, Anatomopathologie
Mots-clés Pascal anglais : Carcinoma, Adenocarcinoma, Undetermined primary site, Histopathology, Differentiation, Cell differentiation, Prognosis, Evolution, Survival, Human, Epidemiology, Malignant tumor, Pathology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0302577
Code Inist : 002B04C. Création : 15/07/1997.